Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Biotech has informed that Concord biotech has made investment of USD 1,000,000 in Compulsorily convertible Notes of Palvella Therapeutics, Inc. In terms of the above referred provisions of the SEBI LODR Regulations, read with circular dated November 11, 2024 issued by the Securities and Exchange Board of India, bearing ref. no. SEBI/HO/CFD/PoD2/CIR/P/0155 (said SEBI Circular). The requisite details of terms of the provisions of Regulation 30 read with Schedule III of the SEBI LODR Regulations and the said SEBI circular, are included in Annexure A, as enclosed.
The above information is a part of company’s filings submitted to BSE.
